Search Results

Deals

PainReform Announces Pricing of $20.0 Million Initial Public Offering

PainReform Ltd. (NasdaqCM:PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the pricing of its initial public offering of 2,500,000 units at a price of $8.00 per unit

September 1, 2020

·

2 min read

Business

PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors

PainReform Ltd. (NASDAQ:PRFX) , welcomes Augustine Lawlor as a member of the Companys Board of Directors following its recent initial public offering.

November 5, 2020

·

4 min read

Business

PainReform Welcomes Successful Healthcare and Capital Markets Executive Dr. Ellen Baron to Board of Directors

PainReform Ltd. welcomes Dr. Ellen Baron as a member of the Company’s Board of Directors following its recent initial public offering.

November 12, 2020

·

3 min read

Business

PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer

PainReform Ltd., a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announced the appointment of Ilan Hadar as Chief Executive Officer.

November 23, 2020

·

4 min read

Drug Development

PainReform Commences Preparations for Pivotal Phase 3 Clinical Trials

PainReform Ltd.today announced that following the closing of its initial public offering, it has commenced preparations for the launch of its pivotal Phase 3 clinical trials of PRF-110 for the treatment of post-operative pain.

September 29, 2020

·

4 min read

PainReform Announces Closing of $20.0 Million Initial Public Offering

PainReform Ltd. (NASDAQ:PRFX) today announced the closing on September 3, 2020 of its initial public offering of 2,500,000 units at a price of $8.00 per unit.

September 9, 2020

·

2 min read

PainReform Highlights Surgical Advantages of PRF-110

PRF-110 addresses potential concerns in the local administration of anesthetic related to wound healing and suture integrity that are commonly involved in surgical procedures

October 19, 2020

·

6 min read

FDA

PainReform Gets FDA Approval for Phase III Post-Operative Pain Relief Study

PainReform Ltd has received FDA approval to conduct two pivotal Phase III clinical trials for post-operative pain relief in soft and hard tissue.

July 18, 2018

·

2 min read

Business

PainReform Licenses a Novel Sustained Release Formulation of Ropivacaine from Encore Therapeutics Inc.

July 2, 2008

·

1 min read